{"id":"cilnidipine","rwe":[{"pmid":"41835736","year":"2026","title":"Hypertension Management Beyond Blood Pressure Control in India: An Expert Consensus on Angiotensin II Receptor Blocker and Calcium Channel Blocker Combination Therapy With Reference to Telmisartan and Cilnidipine.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"41832712","year":"2026","title":"Pharmacokinetic Insights and Therapeutic Potential of Calcium Channel Blockers in Cardiovascular and Non-Cardiovascular Disorders.","finding":"","journal":"Current pharmaceutical design","studyType":"Clinical Study"},{"pmid":"41825721","year":"2026","title":"A fast method to predict solubility of neutral co-crystals in aqueous media.","finding":"","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","studyType":"Clinical Study"},{"pmid":"41714424","year":"2026","title":"Repurposing Cilnidipine as an entry inhibitor against Crimean-Congo Hemorrhagic Fever pseudovirus infection.","finding":"","journal":"Archives of virology","studyType":"Clinical Study"},{"pmid":"41364674","year":"2025","title":"Greenness Assessment of HPLC-UV Method for Simultaneous Estimation of Four Antihypertensive Drugs.","finding":"","journal":"Journal of chromatographic science","studyType":"Clinical Study"}],"tags":[{"label":"cilnidipine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Voltage-dependent T-type calcium channel subunit alpha-1H","category":"target"},{"label":"CACNA1H","category":"gene"},{"label":"CACNA1B","category":"gene"},{"label":"CACNA1C","category":"gene"},{"label":"C08CA14","category":"atc"},{"label":"Active","category":"status"},{"label":"Calcium Channel Blockers","category":"pharmacology"},{"label":"Calcium-Regulating Hormones and Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"}],"phase":"phase_3","safety":{"safetySignals":[{"llr":110.785,"date":"","count":72,"signal":"Renal impairment","source":"DrugCentral FAERS","actionTaken":"Reported 72 times (LLR=111)"},{"llr":95.436,"date":"","count":49,"signal":"Hepatic function abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 49 times (LLR=95)"},{"llr":78.146,"date":"","count":37,"signal":"Cerebral infarction","source":"DrugCentral FAERS","actionTaken":"Reported 37 times (LLR=78)"},{"llr":57.82,"date":"","count":42,"signal":"Interstitial lung disease","source":"DrugCentral FAERS","actionTaken":"Reported 42 times (LLR=58)"},{"llr":50.37,"date":"","count":8,"signal":"Hyperkinetic heart syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 8 times (LLR=50)"},{"llr":48.401,"date":"","count":37,"signal":"Hyperkalaemia","source":"DrugCentral FAERS","actionTaken":"Reported 37 times (LLR=48)"},{"llr":41.649,"date":"","count":40,"signal":"Cardiac failure","source":"DrugCentral FAERS","actionTaken":"Reported 40 times (LLR=42)"},{"llr":40.931,"date":"","count":16,"signal":"Hyperuricaemia","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=41)"},{"llr":40.562,"date":"","count":14,"signal":"Embolic stroke","source":"DrugCentral FAERS","actionTaken":"Reported 14 times (LLR=41)"},{"llr":39.904,"date":"","count":26,"signal":"Cerebral haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 26 times (LLR=40)"},{"llr":38.127,"date":"","count":43,"signal":"Platelet count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 43 times (LLR=38)"},{"llr":38.001,"date":"","count":5,"signal":"Cardiac vein perforation","source":"DrugCentral FAERS","actionTaken":"Reported 5 times (LLR=38)"}],"commonSideEffects":[{"effect":"Renal impairment","drugRate":"LLR 111","severity":"common"},{"effect":"Hepatic function abnormal","drugRate":"LLR 95","severity":"common"},{"effect":"Cerebral infarction","drugRate":"LLR 78","severity":"common"},{"effect":"Interstitial lung disease","drugRate":"LLR 58","severity":"common"},{"effect":"Hyperkinetic heart syndrome","drugRate":"LLR 50","severity":"common"},{"effect":"Hyperkalaemia","drugRate":"LLR 48","severity":"common"},{"effect":"Cardiac failure","drugRate":"LLR 42","severity":"common"},{"effect":"Hyperuricaemia","drugRate":"LLR 41","severity":"common"},{"effect":"Embolic stroke","drugRate":"LLR 41","severity":"common"},{"effect":"Cerebral haemorrhage","drugRate":"LLR 40","severity":"common"},{"effect":"Platelet count decreased","drugRate":"LLR 38","severity":"common"},{"effect":"Cardiac vein perforation","drugRate":"LLR 38","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T12:35:36.483262","allNames":"cinalong","offLabel":[],"synonyms":["FRC-8653","cilnidipine","cinaldipine","cinalong"],"timeline":[],"approvals":[],"brandName":"Cinalong","ecosystem":[],"mechanism":{"target":"Voltage-dependent N-type calcium channel subunit alpha-1B, Voltage-dependent T-type calcium channel subunit alpha-1H, Voltage-gated L-type calcium channel","targets":[{"gene":"CACNA1H","source":"DrugCentral","target":"Voltage-dependent T-type calcium channel subunit alpha-1H","protein":"Voltage-dependent T-type calcium channel subunit alpha-1H","isPrimary":true,"activityType":"IC50","activityValue":4.62},{"gene":"CACNA1B","source":"DrugCentral","target":"Voltage-dependent N-type calcium channel subunit alpha-1B","protein":"Voltage-dependent N-type calcium channel subunit alpha-1B"},{"gene":"CACNA1C","source":"DrugCentral","target":"Voltage-gated L-type calcium channel","protein":"Voltage-dependent L-type calcium channel subunit alpha-1C"},{"gene":"CACNA1D","source":"DrugCentral","target":"Voltage-gated L-type calcium channel","protein":"Voltage-dependent L-type calcium channel subunit alpha-1D"}],"modality":"Small Molecule","drugClass":"cilnidipine","explanation":"Imagine your blood vessels are like roads with traffic lights. Calcium channels are like the traffic lights that control how much blood flows through the roads. Cilnidipine works by blocking these traffic lights, which helps to slow down the flow of blood and lower blood pressure.","oneSentence":"Cilnidipine blocks calcium channels in blood vessels to lower blood pressure.","technicalDetail":"Cilnidipine selectively blocks the voltage-dependent T-type calcium channel subunit alpha-1H, which is involved in the regulation of vascular smooth muscle tone and cardiac function."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/642","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CILNIDIPINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CILNIDIPINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:00:52.885301","biosimilars":[],"competitors":[{"drugName":"amlodipine","drugSlug":"amlodipine","fdaApproval":"1992-07-31","patentExpiry":"Feb 24, 2041","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"felodipine","drugSlug":"felodipine","fdaApproval":"1991-07-25","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"isradipine","drugSlug":"isradipine","fdaApproval":"1990-12-20","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nicardipine","drugSlug":"nicardipine","fdaApproval":"1988-12-21","patentExpiry":"Dec 26, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"nifedipine","drugSlug":"nifedipine","fdaApproval":"1981-12-31","genericCount":24,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nimodipine","drugSlug":"nimodipine","fdaApproval":"1988-12-28","patentExpiry":"Apr 16, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"nisoldipine","drugSlug":"nisoldipine","fdaApproval":"1995-02-02","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"clevidipine","drugSlug":"clevidipine","fdaApproval":"2008-08-01","patentExpiry":"Oct 10, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"celecoxib","drugSlug":"celecoxib","fdaApproval":"1998-12-31","patentExpiry":"May 27, 2036","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"cilnidipine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"_fixedFields":["primaryTarget"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"amlodipine","brandName":"amlodipine","genericName":"amlodipine","approvalYear":"1992","relationship":"same-class"},{"drugId":"felodipine","brandName":"felodipine","genericName":"felodipine","approvalYear":"1991","relationship":"same-class"},{"drugId":"isradipine","brandName":"isradipine","genericName":"isradipine","approvalYear":"1990","relationship":"same-class"},{"drugId":"nicardipine","brandName":"nicardipine","genericName":"nicardipine","approvalYear":"1988","relationship":"same-class"},{"drugId":"nifedipine","brandName":"nifedipine","genericName":"nifedipine","approvalYear":"1981","relationship":"same-class"},{"drugId":"nimodipine","brandName":"nimodipine","genericName":"nimodipine","approvalYear":"1988","relationship":"same-class"},{"drugId":"nisoldipine","brandName":"nisoldipine","genericName":"nisoldipine","approvalYear":"1995","relationship":"same-class"},{"drugId":"clevidipine","brandName":"clevidipine","genericName":"clevidipine","approvalYear":"2008","relationship":"same-class"},{"drugId":"celecoxib","brandName":"celecoxib","genericName":"celecoxib","approvalYear":"1998","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":["Post-stroke Pneumonia"],"enrollment":13656,"completionDate":"2026-08-19"},{"nctId":"NCT02145104","phase":"PHASE3","title":"Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2014-06-17","conditions":["Hypertension"],"enrollment":286,"completionDate":"2016-09-29"},{"nctId":"NCT02343250","phase":"PHASE1","title":"A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination With Coadministration of Cilnidipine and Valsartan","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2015-03","conditions":["Hypertension"],"enrollment":54,"completionDate":""},{"nctId":"NCT02088008","phase":"PHASE1","title":"A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination Tablet With Coadministration of Cilnidipine and Valsartan","status":"UNKNOWN","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2014-05","conditions":["Healthy Volunteers"],"enrollment":54,"completionDate":""},{"nctId":"NCT01838967","phase":"PHASE1","title":"A Drug Interaction Study of Cilnidipine and Valsartan","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2013-04","conditions":["Healthy"],"enrollment":54,"completionDate":"2013-10"},{"nctId":"NCT00890279","phase":"PHASE2","title":"Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)","status":"UNKNOWN","sponsor":"Ministry of Health, Labour and Welfare, Japan","startDate":"2009-07","conditions":["Kidney, Polycystic, Autosomal Dominant"],"enrollment":160,"completionDate":"2012-11"},{"nctId":"NCT00325637","phase":"PHASE3","title":"Cilnidipine Effect on High Blood Pressure and Cerebral Perfusion in Ischemic Stroke Patients With Hypertension","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2005-01","conditions":["Hypertension","Stroke"],"enrollment":250,"completionDate":"2007-08"},{"nctId":"NCT00325936","phase":"PHASE4","title":"The Effects of Cilnidipine on Metabolic Syndrome Improvement","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2005-07","conditions":["Hypertension","Metabolic Syndrome X"],"enrollment":186,"completionDate":"2007-06"},{"nctId":"NCT00541853","phase":"PHASE4","title":"CCB Safety Study in Treatment of Hypertension of ADPKD","status":"UNKNOWN","sponsor":"Kyorin University","startDate":"2007-12","conditions":["Kidney, Polycystic, Autosomal Dominant"],"enrollment":150,"completionDate":"2012-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"010899","UNII":"97T5AZ1JIP","CHEBI":"CHEBI:31399","INN_ID":"6880","UMLSCUI":"C0378675","ChEMBL_ID":"CHEMBL452076","KEGG_DRUG":"D01173","DRUGBANK_ID":"DB09232","PUBCHEM_CID":"5282138","SNOMEDCT_US":"1177123004","IUPHAR_LIGAND_ID":"7767","MESH_SUPPLEMENTAL_RECORD_UI":"C065927"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":338,"therapeuticAreas":["Hematology"],"atcClassification":{"source":"DrugCentral","atcCode":"C08CA14","allCodes":["C08CA14"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb","pmid":"41835736","title":"Hypertension Management Beyond Blood Pressure Control in India: An Expert Consensus on Angiotensin II Receptor Blocker and Calcium Channel Blocker Combination Therapy With Reference to Telmisartan and Cilnidipine.","journal":"Cureus"},{"date":"2026 Mar 11","pmid":"41832712","title":"Pharmacokinetic Insights and Therapeutic Potential of Calcium Channel Blockers in Cardiovascular and Non-Cardiovascular Disorders.","journal":"Current pharmaceutical design"},{"date":"2026 Mar 11","pmid":"41825721","title":"A fast method to predict solubility of neutral co-crystals in aqueous media.","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences"},{"date":"2026 Feb 19","pmid":"41714424","title":"Repurposing Cilnidipine as an entry inhibitor against Crimean-Congo Hemorrhagic Fever pseudovirus infection.","journal":"Archives of virology"},{"date":"2025 Nov 15","pmid":"41364674","title":"Greenness Assessment of HPLC-UV Method for Simultaneous Estimation of Four Antihypertensive Drugs.","journal":"Journal of chromatographic science"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cilnidipine is a small molecule that acts as a voltage-gated L-type calcium channel blocker. It has been studied in clinical trials for conditions such as hypertension, stroke, and metabolic syndrome X.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}